{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:59:39Z","timestamp":1787169579282,"version":"build-2736575974"},"reference-count":10,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2024,12,19]]},"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:p>Denosumab, an anti-RANKL antibody, induces bone metabolism to a low-turnover bone status by arresting osteoclast activity. Frequent adverse events include infusion reactions, fever and hypocalcaemia but not hypophosphataemia. We report a case of severe hypophosphataemia associated with secondary hyperparathyroidism following denosumab administration in a young boy with recurrent osteosarcoma who was successfully treated with evocalcet. He developed hypocalcaemia and severe refractory hypophosphataemia after receiving denosumab for bone metastases despite calcium, cholecalciferol and phosphorus supplementation. Laboratory data revealed secondary hyperparathyroidism due to denosumab-induced hypocalcaemia as the cause of hypophosphataemia. Evocalcet contributed to the normalised parathyroid hormone and phosphorus levels, allowing the discontinuation of phosphorus supplementation. This case highlights the complexity of managing electrolyte imbalances induced by bone-modifying agents, such as denosumab, underscoring the importance of monitoring bone metabolism markers and the potential effectiveness of evocalcet in managing drug-induced secondary hyperparathyroidism and hypophosphataemia.<\/jats:p>","DOI":"10.1136\/bcr-2024-263129","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T09:01:06Z","timestamp":1736326866000},"page":"e263129","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Severe hypophosphataemia following denosumab administration successfully managed using a calcimimetic agent"],"prefix":"10.1136","volume":"18","author":[{"given":"Makiko","family":"Omori","sequence":"first","affiliation":[{"name":"Pediatrics, Shiga University of Medical Science, Otsu, Shiga, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3974-5985","authenticated-orcid":false,"given":"Yukihiro","family":"Matsukawa","sequence":"additional","affiliation":[{"name":"Pediatrics, Shiga University of Medical Science, Otsu, Shiga, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhachi","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Pediatrics, Shiga University of Medical Science, Otsu, Shiga, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Sakai","sequence":"additional","affiliation":[{"name":"Pediatrics, Shiga University of Medical Science, Otsu, Shiga, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,1,8]]},"reference":[{"key":"2025082801033968000_18.1.e263129.1","doi-asserted-by":"crossref","first-page":"272","DOI":"10.4103\/2278-330X.119895","article-title":"Denosumab: A comprehensive review","volume":"2","author":"Narayanan","year":"2013","journal-title":"South Asian J Cancer"},{"key":"2025082801033968000_18.1.e263129.2","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1210\/jc.2015-1259","article-title":"Effects of Denosumab and Calcitriol on Severe Secondary Hyperparathyroidism in Dialysis Patients With Low Bone Mass","volume":"100","author":"Chen","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2025082801033968000_18.1.e263129.3","article-title":"Diagnosis and Management of Denosumab-Induced Hypocalcemia and Hypophosphatemia in the Setting of Metastatic Prostate Cancer","volume":"14","author":"Flood","year":"2022","journal-title":"Cureus"},{"key":"2025082801033968000_18.1.e263129.4","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s40264-019-00888-1","article-title":"Drug-Induced Hypophosphatemia: Current Insights","volume":"43","author":"Megapanou","year":"2020","journal-title":"Drug Saf"},{"key":"2025082801033968000_18.1.e263129.5","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/ajco.12517","article-title":"Denosumab: Prevention and management of hypocalcemia, osteonecrosis of the jaw and atypical fractures","volume":"13","author":"Pittman","year":"2017","journal-title":"Asia Pac J Clin Oncol"},{"key":"2025082801033968000_18.1.e263129.6","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1210\/clinem\/dgad657","article-title":"Management of RANKL-mediated Disorders With Denosumab in Children and Adolescents: A Global Expert Guidance Document","volume":"109","author":"Vanderniet","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2025082801033968000_18.1.e263129.7","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/1744-9987.13434","article-title":"Evocalcet: A New Oral Calcimimetic for Dialysis Patients With Secondary Hyperparathyroidism","volume":"24","author":"Akizawa","year":"2020","journal-title":"Ther Apher Dial"},{"key":"2025082801033968000_18.1.e263129.8","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.2169\/internalmedicine.9261-21","article-title":"Successful Control of Hypercalcemia with Sorafenib, Evocalcet, and Denosumab Combination Therapy for Recurrent Parathyroid Carcinoma","volume":"61","author":"Makino","year":"2022","journal-title":"Intern Med"},{"key":"2025082801033968000_18.1.e263129.9","doi-asserted-by":"publisher","DOI":"10.3122\/jabfm.2009.05.090026"},{"key":"2025082801033968000_18.1.e263129.10","doi-asserted-by":"crossref","DOI":"10.1186\/s12894-018-0393-9","article-title":"Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: prevention supports treatment completion","volume":"18","author":"Body","year":"2018","journal-title":"BMC Urol"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2024-263129","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T08:03:47Z","timestamp":1756368227000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2024-263129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,8]]},"published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1136\/bcr-2024-263129"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2024-263129","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]}}}